JPH0524892B2 - - Google Patents
Info
- Publication number
- JPH0524892B2 JPH0524892B2 JP60064692A JP6469285A JPH0524892B2 JP H0524892 B2 JPH0524892 B2 JP H0524892B2 JP 60064692 A JP60064692 A JP 60064692A JP 6469285 A JP6469285 A JP 6469285A JP H0524892 B2 JPH0524892 B2 JP H0524892B2
- Authority
- JP
- Japan
- Prior art keywords
- arbutin
- skin diseases
- agent
- drug
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 17
- 229960000271 arbutin Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 description 5
- 208000010247 contact dermatitis Diseases 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000118 hair dye Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
＜産業上の利用分野＞
本発明は皮膚疾患用剤、更に詳しくは副腎皮質
ホルモン剤と、ウワウルシ又はその主成分である
アルブチンを含有する皮膚疾患用剤に関する。
＜従来技術＞
副腎皮質ホルモンは副腎皮質より分沁される
種々の生物活性を有するホルモンであり、天然品
の他種々の合成品があり、薬剤としてアルギー性
疾患、炎症性疾患等にも有効であることが知られ
ている。
一方、ウワウルシは日本薬局方にも収載されて
いる如く、その抗菌作用により尿路防腐剤として
用いられるものである。
＜発明の効果＞
本発明者等は、各種皮膚疾患殊にアルギー性炎
症（接触性皮膚炎）の予防、治療効果について検
討を行う過において、副腎皮質ホルモン剤にウワ
ウルシ又はその主成分であるアルブチンを配合し
た場合、それぞれを単独使用した場合に比較し著
るしく優れた予防治療効果を呈することを見い出
し本発明を完成した。
本発明の皮膚疾患用剤は、各種皮膚疾患例えば
接触性皮膚炎、アトピー性皮膚炎、脂漏性皮膚
炎、日光性皮膚炎、薬疹、皮膚痒症、殊に前二
者に有効に使用できる。
これ等皮膚疾患に対する本発明の皮膚疾患用剤
の投与方法としては、注射、経口、外用のいずれ
でも可能である特に外用剤として投与するのが望
ましい。
本発明に係わる外用剤は製剤中に副腎皮質ホル
モン剤を0.1〜0.5％含有させ、これにウワウルシ
の場合１〜10％、アルブチンの場合0.1〜５％を
含有させ、更に製剤上繁用される適当な添加剤、
賦形剤等を混合し軟膏、クリーム、液剤等とする
ことにより製しうる。
以下実施例にて本発明を説明する。
実施例 １
ピクリンクロライド接触性皮膚炎（PC−CD）
に対する内服投与による予防及び治療効果
実験動物及び実験試薬；
実験動物としてはマウスを、試薬としてはウワ
ウルシの50％メタノール抽出エキス、アルブチン
及び副腎皮質ホルモン剤としてプレドニゾロンを
用いた。
実験方法；
ピクリンクロライドのエタノール溶液を実験動
物の腹部に塗布し感作させ、１週間後に耳朶塗布
を行い誘発させた。
予防効果の実験は、誘発直前と誘発後16時間目
の２回各試薬を投与し、治療効果の実験は、誘発
後28時間目に各試薬を投与して投与前後における
腫脹度の変化を測定し効果を比較検討した。な
お、ウワウルシ及びアルブチンは経口投与（P.
O）でプレドニゾロンは皮下注射（S.C）で行な
つた。
結果： 予防及び治療効果は下記表−１及び表−
２に示される。
<Industrial Field of Application> The present invention relates to an agent for skin diseases, and more particularly to an agent for skin diseases containing an adrenocortical hormone agent and urticaria or arbutin, its main component. <Prior art> Adrenocortical hormone is a hormone that is secreted from the adrenal cortex and has various biological activities.There are natural products as well as various synthetic products, and it is effective as a drug for algic diseases, inflammatory diseases, etc. It is known that there is. On the other hand, Uwa urushi is used as a urinary tract preservative due to its antibacterial action, as is also listed in the Japanese Pharmacopoeia. <Effects of the Invention> In the course of investigating the preventive and therapeutic effects of various skin diseases, particularly algic inflammation (contact dermatitis), the present inventors discovered that urticaria or its main component, arbutin, was added to corticosteroids. The present invention has been completed based on the discovery that when combined, a significantly superior preventive and therapeutic effect is exhibited compared to when each is used alone. The agent for skin diseases of the present invention can be effectively used for various skin diseases such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, solar dermatitis, drug eruption, and pruritus, especially the first two. can. The method of administering the agent for skin diseases of the present invention for these skin diseases can be by injection, orally, or externally, and it is particularly desirable to administer it as an external preparation. The external preparation according to the present invention contains 0.1 to 0.5% of an adrenocortical hormone agent in the preparation, 1 to 10% in the case of Uwa Urushi, and 0.1 to 5% in the case of Arbutin, and further contains 0.1 to 0.5% of the adrenocortical hormone agent in the preparation. suitable additives,
It can be manufactured by mixing excipients and the like to form ointments, creams, liquids, etc. The present invention will be explained below with reference to Examples. Example 1 Picrin chloride contact dermatitis (PC-CD)
Preventive and therapeutic effects of oral administration on experimental animals and experimental reagents: Mice were used as the experimental animals, 50% methanol extract of Uwa sumac, arbutin, and prednisolone as the adrenocorticosteroid were used as the reagents. Experimental method: An ethanol solution of picrin chloride was applied to the abdomen of the experimental animal to sensitize it, and one week later it was applied to the earlobe for induction. For the preventive effect experiment, each reagent was administered twice, immediately before induction and 16 hours after induction, and for the therapeutic effect experiment, each reagent was administered 28 hours after induction and changes in the degree of swelling before and after administration were measured. The effects were compared and examined. In addition, urushi and arbutin can be administered orally (P.
O) Prednisolone was administered subcutaneously (SC). Results: The preventive and therapeutic effects are shown in Table-1 and Table- below.
2.
【表】【table】
【表】
実施例 22
本発明合剤の製法
下記処方例１及び２により外用剤を製した。
処方例 １
軟膏
アルブチン ５ｇ
ピレドニゾロン 0.25ｇ
白色ワセリン 86.75ｇ
コレステロール 3.0ｇサラシミツロウ 5.0
以上の処方で軟膏を製した。
処方例 ２
ｏ／ｗ型クリーム
アルブチン 5.0ｇ
吉草酸ベタメサゾン 0.06ｇ
セチルアルコール 25.0ｇ
白色ワセリン 25.0ｇ
ステアリン酸ポリオキシル 5.0ｇ
パラオキシ安息香酸ブチル 0.05ｇ精製水で全量 100ｇ
以上の処方でｏ／ｗ型クリーム剤を製した。
実施例 ３
実施例２の処方例１の軟膏を使用した臨床的に
合剤の効果を評価した。
症例 １
マユズミによる接触性皮膚炎（45才、女性）
使用部位に痒を伴なう強度の紅斑が出現して
来院、本剤を数回外用塗布することにより、１日
後に紅班は軽度となり、３日後に治癒した。
症例 ２
ヘアダイ（染毛剤）接触性皮膚炎（51才、女
性）
ヘアダイ使用により毛髪生え際に紅斑，腫脹の
発現をみて来院した。本剤を１日３回外用塗布し
たところ２日後に紅斑、３日後に腫脹も消退し５
日後に完治した。
症例 ３
アトピー性皮膚炎（５才男性）
乳児期より四肢大関節屈側部に強い痒を伴な
う皮疹がみられており、副腎ホルモン剤により治
療しているが投薬中止により再発をしていた。今
回、副腎皮質ホルモン剤のベトネベートＮ軟膏と
本剤とを併用したところ、ベトネベートの単独投
与に比較して皮疹が軽減し、また再発時期の遅延
化がみられた。[Table] Example 22 Method for producing the mixture of the present invention External preparations were produced according to Formulation Examples 1 and 2 below. Prescription Example 1 Ointment Arbutin 5g Pyrednisolone 0.25g White petrolatum 86.75g Cholesterol 3.0g White beeswax An ointment was prepared using a prescription of 5.0 or higher. Prescription example 2 O/W type cream Arbutin 5.0g Betamethasone valerate 0.06g Cetyl alcohol 25.0g White petrolatum 25.0g Polyoxyl stearate 5.0g Butyl paraoxybenzoate 0.05g Total amount with purified water O/W type cream for prescriptions of 100g or more was manufactured. Example 3 The effect of the combination was clinically evaluated using the ointment of Prescription Example 1 of Example 2. Case 1 Contact dermatitis caused by Cocoa rubella (45-year-old female) She came to the hospital with severe erythema accompanied by itching at the application site, and by applying this drug topically several times, the erythema became mild after 1 day. , healed after 3 days. Case 2: Hair dye (hair dye) contact dermatitis (51-year-old female) The patient visited our hospital because of erythema and swelling at the hairline due to the use of hair dye. When this drug was applied externally three times a day, the erythema disappeared after 2 days and the swelling disappeared after 3 days.
He recovered completely within a day. Case 3: Atopic dermatitis (5-year-old male) A skin eruption with severe itching has been observed on the flexor side of the large joints of the extremities since infancy. Although he has been treated with adrenal hormones, it has recurred after discontinuing the medication. Ta. This time, when this drug was used in combination with Betnevate N ointment, an adrenal corticosteroid, the skin rash was reduced and the time of recurrence was delayed compared to the administration of Betnevate alone.
Claims (1)
主成分であるアルブチンを含有する皮膚疾患用
剤。1. A drug for skin diseases containing an adrenocortical hormone agent and Urushi ursi or its main component, arbutin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60064692A JPS61225124A (en) | 1985-03-28 | 1985-03-28 | Drug for dermatopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60064692A JPS61225124A (en) | 1985-03-28 | 1985-03-28 | Drug for dermatopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61225124A JPS61225124A (en) | 1986-10-06 |
| JPH0524892B2 true JPH0524892B2 (en) | 1993-04-09 |
Family
ID=13265451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60064692A Granted JPS61225124A (en) | 1985-03-28 | 1985-03-28 | Drug for dermatopathy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61225124A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744366B1 (en) * | 1996-02-06 | 1998-03-27 | Serobiologiques Lab Sa | USE OF EXTRACTS FROM UVA URSI PLANT AND / OR LESPEDEZA CAPITATA PLANT AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH EXTRACTS |
-
1985
- 1985-03-28 JP JP60064692A patent/JPS61225124A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61225124A (en) | 1986-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4542129A (en) | DHEA Formulations and methods for treating dry skin | |
| US4743597A (en) | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases | |
| KR100952786B1 (en) | Pharmaceutical composition | |
| US4784994A (en) | Process for the treatment of inflammatory and allergic diseases | |
| US4879274A (en) | External medication for skin | |
| US6093745A (en) | Methods and composition for treating skin proliferative diseases | |
| EP3411014B1 (en) | New topical compositions comprising usnic acid and their use in therapy | |
| JPH03204815A (en) | Therapeutic composition for treating dermatological disease carried by mast cell | |
| JP4387463B2 (en) | Treatment of psoriasis with tazarotene and corticosteroids | |
| EP0352826A2 (en) | Use of 5-aminosalicylic acid in the treatment of dermatological disorders | |
| JPH0524892B2 (en) | ||
| Kubo et al. | Contact dermatitis from ibuprofen piconol. | |
| JP2860550B2 (en) | Acute skin inflammation treatment | |
| JPH03505572A (en) | Topically applied gold organic complex | |
| JPH11302167A (en) | Ufenamate preparation for external use | |
| WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
| US20030064081A1 (en) | Topical anti-pruritic composition | |
| JP3193028B2 (en) | External preparation for treating atopic dermatitis containing nitroimidazole compound | |
| JP2001163783A (en) | Agent for external use for treating dermatosis | |
| Kowalzick et al. | An Open pilot study of topical calcipotriol in seborrhoeic eczema | |
| WO2006119540A1 (en) | Preparation for treating psoriasis | |
| JPH06100451A (en) | Skin external agent | |
| JP3187806B2 (en) | External preparation for treating atopic dermatitis containing nitroimidazole compound | |
| JP3568881B2 (en) | External preparation for skin disease treatment | |
| JPS58164516A (en) | Remedy for eczematoid skin disease and drug rash |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |